2019
Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder
Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. Clinical Psychological Science 2019, 7: 1190-1206. PMID: 32042509, PMCID: PMC7009780, DOI: 10.1177/2167702619855659.Peer-Reviewed Original ResearchOpioid use disorderClinical featuresUse disordersHigher anhedonia scoresKey clinical featuresRate of participantsAnhedonia scoresOpioid-dependent sampleOpioid cravingOpioid useTreatment adherenceHealthy controlsSignificant anhedoniaPharmacological interventionsAssessment of anhedoniaMajority of studiesPotential targetAnhedoniaTreatmentTime courseDisordersSignificant knowledge gapsScoresPotential implicationsCritical needGambling disorder
Potenza MN, Balodis IM, Derevensky J, Grant JE, Petry NM, Verdejo-Garcia A, Yip SW. Gambling disorder. Nature Reviews Disease Primers 2019, 5: 51. PMID: 31346179, DOI: 10.1038/s41572-019-0099-7.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialOpioid receptor antagonistGambling disorderCognitive behavioral therapyPharmacological therapyLimbic structuresPsychiatric disordersAdult populationSubstantial distressClinical settingBehavioral interventionsTreatment effortsDisordersTherapyPoor qualityFormal indicationNeurobiological studiesTreatmentImproved identificationMedicationsPathophysiologyEtiologyAntagonistPrevalenceGamblers Anonymous
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipantsThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease
2016
Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment
Yip SW, Potenza MN. Application of Research Domain Criteria to childhood and adolescent impulsive and addictive disorders: Implications for treatment. Clinical Psychology Review 2016, 64: 41-56. PMID: 27876165, PMCID: PMC5423866, DOI: 10.1016/j.cpr.2016.11.003.Peer-Reviewed Original Research